Literature DB >> 11260280

Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia.

J M Soucie1, J Symons, B Evatt, D Brettler, H Huszti, J Linden.   

Abstract

Information from the medical records of 2650 US males with haemophilia living in six states was used to examine the influence of infusing factor concentrate at home (home therapy) and other variables on rates of hospitalization for a haemorrhagic bleeding complication (HBC) over a 4-year period. Bleeding complications included actual and suspected haemorrhagic events but excluded elective admissions for procedures necessitated by haemorrhage (e.g. joint synovectomy). Other risk determinants considered in the analyses included age, race, employment status, health insurance type, care received in federally funded haemophilia treatment centres (HTCs), factor deficiency type and severity, amount of factor prescribed, prophylactic treatment, and presence of inhibitors at baseline. Survival analysis methods were used to evaluate relationships between baseline risk factors and subsequent hospitalization rates. During 8708 person years (PYs) of follow-up, 808 subjects (30.5%) had a total of 1847 bleeding-related hospitalizations; an overall rate of 21.2 admissions per 100 PYs. Using proportional hazards regression to adjust for all of the studied factors, we found that home therapy use (among residents of four of the states) and care in HTCs were independently associated with a decreased risk for a first HBC. Patients who had government-sponsored health insurance or who had no insurance, those of minority race or ethnicity, those with higher levels of factor use, and those with inhibitors were at increased HBC risk. We conclude that the use of home therapy and receipt of care in HTCs are each associated with a substantially lower risk for HBC among males with haemophilia.

Entities:  

Mesh:

Year:  2001        PMID: 11260280     DOI: 10.1046/j.1365-2516.2001.00484.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  29 in total

1.  Public health surveillance and data collection: general principles and impact on hemophilia care.

Authors:  J Michael Soucie
Journal:  Hematology       Date:  2012-04       Impact factor: 2.269

Review 2.  New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.

Authors:  Margaret V Ragni
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 3.  The national haemophilia program standards, evaluation and oversight systems in the United States of America.

Authors:  Mark W Skinner; J Michael Soucie; Kathryn Mclaughlin
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 4.  Systems-based hematology: highlighting successes and next steps.

Authors:  Jori E May; Patrick C Irelan; Kailee Boedeker; Emily Cahill; Steven Fein; David A Garcia; Lisa K Hicks; Janice Lawson; Ming Y Lim; Colleen T Morton; Anita Rajasekhar; Satish Shanbhag; Marc S Zumberg; Robert M Plovnick; Nathan T Connell
Journal:  Blood Adv       Date:  2020-09-22

5.  Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis.

Authors:  Craig D Seaman; Margaret V Ragni
Journal:  Blood Adv       Date:  2017-07-18

6.  A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders.

Authors:  Judith R Baker; Sally O Crudder; Brenda Riske; Val Bias; Ann Forsberg
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

7.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.

Authors:  Tom Bowen; Marco Cicardi; Henriette Farkas; Konrad Bork; Hilary J Longhurst; Bruce Zuraw; Emel Aygoeren-Pürsün; Timothy Craig; Karen Binkley; Jacques Hebert; Bruce Ritchie; Laurence Bouillet; Stephen Betschel; Della Cogar; John Dean; Ramachand Devaraj; Azza Hamed; Palinder Kamra; Paul K Keith; Gina Lacuesta; Eric Leith; Harriet Lyons; Sean Mace; Barbara Mako; Doris Neurath; Man-Chiu Poon; Georges-Etienne Rivard; Robert Schellenberg; Dereth Rowan; Anne Rowe; Donald Stark; Smeeksha Sur; Ellie Tsai; Richard Warrington; Susan Waserman; Rohan Ameratunga; Jonathan Bernstein; Janne Björkander; Kristylea Brosz; John Brosz; Anette Bygum; Teresa Caballero; Mike Frank; George Fust; George Harmat; Amin Kanani; Wolfhart Kreuz; Marcel Levi; Henry Li; Inmaculada Martinez-Saguer; Dumitru Moldovan; Istvan Nagy; Erik W Nielsen; Patrik Nordenfelt; Avner Reshef; Eva Rusicke; Sarah Smith-Foltz; Peter Späth; Lilian Varga; Zhi Yu Xiang
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

8.  Septic arthritis in males with haemophilia.

Authors:  A A Ashrani; N S Key; J Michael Soucie; N Duffy; A Forsyth; S Geraghty
Journal:  Haemophilia       Date:  2008-02-21       Impact factor: 4.287

Review 9.  Care models in the management of haemophilia: a systematic review.

Authors:  C H T Yeung; N Santesso; M Pai; C Kessler; N S Key; M Makris; T Navarro-Ruan; J M Soucie; H J Schünemann; A Iorio
Journal:  Haemophilia       Date:  2016-07       Impact factor: 4.287

10.  The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.

Authors:  Marnie Bertolet; Maria M Brooks; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.